{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:11:24Z","timestamp":1780701084778,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-03980-0","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T10:09:26Z","timestamp":1738318166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaolong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"12","key":"3980_CR1","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1681\/ASN.2016010093","volume":"27","author":"X Xu","year":"2016","unstructured":"Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27(12):3739\u201346.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3980_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco N, Guti\u00e9rrez E, Covars\u00ed A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697\u2013704.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3980_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000506948","volume":"144","author":"H Trujillo","year":"2020","unstructured":"Trujillo H, Alonso M, Praga M. New ways of understanding membranous nephropathy. Nephron. 2020;144(6):261\u201371.","journal-title":"Nephron"},{"issue":"4S","key":"3980_CR4","first-page":"S1","volume":"100","author":"Kidney Disease","year":"2021","unstructured":"Kidney Disease. Improving global outcomes glomerular diseases Work G.Kdigo 2021 clinical practice guideline for the management of. Glomerular Dis Kidney Int. 2021;100(4S):S1\u2013276.","journal-title":"Glomerular Dis Kidney Int"},{"key":"3980_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.intimp.2019.03.002","volume":"70","author":"D Liu","year":"2019","unstructured":"Liu D, Yang Y, Kuang F, Qing S, et al. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: a pairwise and network meta-analysis. Int Immunopharmacol. 2019;70:354\u201361.","journal-title":"Int Immunopharmacol"},{"key":"3980_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/TCRM.S399218","volume":"19","author":"S Liang","year":"2023","unstructured":"Liang S, Liang YJ, Li Z, et al. Evaluating efficacy and safety of tacrolimus treatment in membranous nephropathy: results of a retrospective study of 182 patients. Ther Clin Risk Manag. 2023;19:351\u201360.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"3980_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","volume":"93","author":"AE Van de Logt","year":"2018","unstructured":"Van de Logt AE, Dahan K, Rousseau A, et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93(4):1016\u20137.","journal-title":"Kidney Int"},{"issue":"2","key":"3980_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","volume":"1","author":"M Waldman","year":"2016","unstructured":"Waldman M, Beck LH Jr, Braun M, et al. Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and Rituximab. Kidney Int Rep. 2016;1(2):73\u201384.","journal-title":"Kidney Int Rep"},{"key":"3980_CR9","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.2147\/IJGM.S410169","volume":"16","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhang S, Hu R, et al. The safety and efficacy of rituximab-based regimen in atypical membranous nephropathy: a single center retrospective cohort study. Int J Gen Med. 2023;16:1983\u201393. Published 2023 May 23.","journal-title":"Int J Gen Med"},{"issue":"9","key":"3980_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"50","key":"3980_CR11","doi-asserted-by":"publisher","first-page":"e5320","DOI":"10.1097\/MD.0000000000005320","volume":"95","author":"S Yin","year":"2016","unstructured":"Yin S, He T, Li Y, et al. Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: a MOOSE-compliant meta-analysis. Med (Baltim). 2016;95(50):e5320.","journal-title":"Med (Baltim)"},{"key":"3980_CR12","doi-asserted-by":"publisher","first-page":"1323334","DOI":"10.3389\/fphar.2023.1323334","volume":"14","author":"Y Guo","year":"2023","unstructured":"Guo Y, Zhao H, Ren M, et al. Efficacy and safety of Rituximab in elderly patients with membranous nephropathy. Front Pharmacol. 2023;14:1323334.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3980_CR13","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32(4):972\u201382.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3980_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36\u201346.","journal-title":"N Engl J Med"},{"key":"3980_CR15","doi-asserted-by":"publisher","first-page":"1156470","DOI":"10.3389\/fimmu.2023.1156470","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Huang J, Dong J, et al. Efficacy and safety of Rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study. Front Immunol. 2023;14:1156470. Published 2023 Apr 28.","journal-title":"Front Immunol"},{"issue":"1","key":"3980_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348\u201358.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3980_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1681\/ASN.2017040367","volume":"29","author":"E Schrezenmeier","year":"2018","unstructured":"Schrezenmeier E, Jayne D, D\u00f6rner T. Targeting b cells and plasma cells in glomerular diseases: translational perspectives. J Am Soc Nephrol. 2018;29(3):741\u201358.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"3980_CR18","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1007\/s10238-023-01183-1","volume":"23","author":"Q Ma","year":"2023","unstructured":"Ma Q, Li M, Xu G. Combination of Rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A2 receptor antibody positive idiopathic membranous nephropathy. Clin Exp Med. 2023;23(8):5337\u201343.","journal-title":"Clin Exp Med"},{"issue":"4","key":"3980_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4274\/balkanmedj.galenos.2023.2022-9-7","volume":"40","author":"X Chen","year":"2023","unstructured":"Chen X, Jiao S, Li S, et al. Combination of Rituximab and low-dose tacrolimus in the treatment of refractory membranous nephropathy: a retrospective cohort study. Balkan med J. 2023;40(4):287\u201393.","journal-title":"Balkan med J"},{"key":"3980_CR20","doi-asserted-by":"publisher","first-page":"1044782","DOI":"10.3389\/fendo.2023.1044782","volume":"14","author":"P Chen","year":"2023","unstructured":"Chen P, Mao M, Wang C, et al. Preliminary study on the efficacy of Rituximab in the treatment of idiopathic membranous nephropathy: a single-center experience. Front Endocrinol (Lausanne). 2023;14:1044782. Published 2023 Feb 15.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"3980_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.11791018","volume":"14","author":"B Seitz-Polski","year":"2019","unstructured":"Seitz-Polski B, Dahan K, Debiec H, et al. High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin J Am Soc Nephrol. 2019;14(8):1173\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"3980_CR22","first-page":"1691","volume":"32","author":"G Moroni","year":"2017","unstructured":"Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transpl. 2017;32(10):1691\u20136.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"3980_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3109\/0886022X.2015.1007804","volume":"37","author":"T Soleymanian","year":"2015","unstructured":"Soleymanian T, Hamid G, Arefi M, et al. Nondiabetic renal disease with or without diabetic nephropathy in type 2 diabetes: clinical predictors and outcome. Ren Fail. 2015;37(4):572\u20135.","journal-title":"Ren Fail"},{"key":"3980_CR24","doi-asserted-by":"crossref","unstructured":"Qian Y, Zuo K, Li S, Zeng C et al. Membranous nephropathy occurring with type 2 diabetes mellitus. Clin Nephrol. 2017;87 (2017)(3):140\u2013146.","DOI":"10.5414\/CN108951"},{"issue":"2","key":"3980_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11255-019-02348-2","volume":"52","author":"H Xie","year":"2020","unstructured":"Xie H, Li C, Wen Y, et al. Association of diabetes with failure to achieve complete remission of idiopathic membranous nephropathy. Int Urol Nephrol. 2020;52(2):337\u201342.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"3980_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3897\/folmed.65.e85472","volume":"65","author":"IY Zdravkova","year":"2023","unstructured":"Zdravkova IY, Tilkiyan EE, Bozhkova DM. Lectin complement pathway and diabetes mellitus in the pathogenesis of membranous nephropathy. Folia Med (Plovdiv). 2023;65(4):597\u2013604.","journal-title":"Folia Med (Plovdiv)"},{"issue":"10","key":"3980_CR27","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase a2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545\u201358.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03980-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-03980-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03980-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T10:09:31Z","timestamp":1738318171000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-03980-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3980"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-03980-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5651599\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed by the Medical Ethics Committee of the General Hospital of the People\u2019s Liberation Army of China ((Approval No: S2024-319-01). The requirement for written informed consent was waived by this institution because of the retrospective nature of the study. The decision letter of the Ethics Committee covered patient data confidentiality and compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial"}}],"article-number":"49"}}